Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat patients with Binge Eating Disorder (BED) using psilocybin-assisted therapy.
About Tryp Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company that focuses on the development of psilocybin-related molecules which include TRP-8803 designed for treatment of diseases with unmet medical needs through accelerated regulatory pathways.
The company’s Psilocybin For Neuropsychiatric Disorders (PFN™) program focuses on developing synthetic psilocybin-related molecules that can be created as a new class of drug for the treatment of binge eating, chronic pain, and other indications.
Currently Tryp Therapeutics is enrolling patients in a Phase II clinical trial in partnership with the University of Florida for the treatment of binge eating disorder along with a planned upcoming Phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia.
The company’s proprietary psilocybin-based drug, known as TRP-8803, uses a novel formulation and route of administration that may improve efficacy, safety, and the patient experience.
Tryp Therapeutics New Patent Application of Psilocybin Treatment for Binge Eating Disorder
The new Tryp Therapeutics patent application is part of the firm’s overall strategy to increase psilocybin-assisted treatment’s clinical usefulness in individuals with BED who are waiting for transformative medicines.
The first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED is represented by Tryp’s Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial, which was conducted in collaboration with the University of Florida.
The first set of data for the STOP trial’s first patient treated revealed potential benefit for those with BED, further cementing the company’s commitment to developing psilocybin-based treatments for those suffering from eating disorders.
The new Tryp patent will give them Intellectual Property Protection for BED using their psilocybin-based candidates TRP-8802 and TRP-8803, which have been filed.
Tryp is using TRP-8802 to investigate the usage of psilocybin-related chemicals in early stages of clinical research for certain neuropsychiatric diseases. In disorders where efficacy is shown, Tryp’s lead drug candidate, TRP-8803, which is being developed simultaneously, will be studied in later studies.
The TRP-8803 compound is a unique supplement that aims to increase the benefits of psilocybin and other psilocybin-related chemicals while reducing the drawbacks of psilocybin taken by means of different administration techniques, including oral, nasal, and sublingual.
